MediWound Ltd. has entered into an underwriting agreement to issue and sell 1.2 million ordinary shares at a public offering price of $12.50 per share. This offering is expected to raise approximately $17.25 million before expenses. The company intends to use the proceeds primarily for working capital and general corporate purposes.

The offering is significant for MediWound as it seeks to enhance its financial position and support ongoing projects. The deal was made with H.C. Wainwright & Co., LLC, which has also exercised an option to purchase an additional 180,000 shares, bringing the total offering to 1.38 million shares.

The medicinal chemicals and botanical products industry may experience shifts as companies like MediWound secure new funding. This could prompt competitors to reassess their financial strategies and market approaches.

The offering is being conducted under the company’s existing shelf registration statement, which was declared effective in March 2025. The gross proceeds from the offering will be used to strengthen MediWound’s working capital and support its corporate initiatives.

According to the filing, the offering is expected to close on or about November 5, 2026, subject to customary closing conditions. The underwriting agreement includes standard representations and warranties, and the company has agreed to certain restrictions on issuing additional shares for a period following the offering.

In addition to the underwriting agreement, MediWound will reimburse the underwriter for legal fees and other expenses, totaling approximately $100,000, along with additional costs for clearing and performance bonuses.

As the medicinal chemicals industry evolves, MediWound’s ability to secure this funding could position it favorably in a competitive landscape. The company’s next steps will likely include utilizing the funds raised to advance its strategic goals.

Details were not available in the SEC filing regarding further actions or specific projects that will be funded by this offering.